Overview Financials News + Filings Key Docs Ownership Insiders
|
|
Inhibikase Therapeutics, Inc.
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| | 10-K | 10-K | 10-K | 10-K | S-1/A |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | 0.0% | 0.0% | 503.5% | 227.4% | 90.3% |
| Gross profit | 100.0% | 100.0% | -403.5% | -127.4% | 9.7% |
| Selling, general and administrative | 5036.5% | 209.9% | 0.0% | 380.2% | 62.3% |
| Research and development | 9749.7% | 366.4% | | | |
| General and administrative | | | 0.0% | | |
| EBIT | -14686.2% | -476.2% | -201.1% | -507.5% | -52.5% |
| Pre-tax income | -14625.9% | -476.9% | -407.7% | -509.7% | -53.3% |
| Income taxes | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -14625.9% | -476.9% | -407.7% | -509.7% | -53.3% |
|